GABA: the brain’s primary inhibitory neurotransmitter

Chemistry, synthesis and metabolism

Chemically, GABA is an amino acid (gamma‑amino butyric acid) but it is not one of the alpha amino acids used to construct proteins; it is therefore described as non‑proteinogenic. Its immediate precursor in the brain is glutamate, which is converted to GABA by the enzyme glutamic acid decarboxylase (GAD). This reaction requires the cofactor pyridoxal phosphate (vitamin B6). GABA is inactivated primarily by enzymatic degradation: the main route is transamination by GABA transaminase to form succinic semialdehyde, which is further oxidized to succinate and can enter the tricarboxylic acid cycle.

Receptors and mechanisms of action

GABA acts through two major receptor families that differ in mechanism and timescale:

• GABA-A receptors are ligand‑gated chloride channels (ionotropic). When activated they typically allow Cl− to flow across the membrane, producing fast inhibitory postsynaptic potentials that reduce neuronal firing probability.
• GABA-B receptors are G‑protein‑coupled (metabotropic) receptors that modulate ion channels and second‑messenger systems to generate slower, longer‑lasting inhibitory effects.

Some organisms and brain regions express variants often grouped historically as GABA‑C or GABA‑A rho receptors; these also form chloride channels with distinct pharmacology. In immature neurons the intracellular chloride concentration can be high, so activation of GABA receptors may depolarize rather than hyperpolarize cells — a developmental reversal that influences neurodevelopmental processes.

Physiological roles and examples

GABAergic signalling contributes to many basic functions: controlling cortical rhythms, shaping sensory processing, coordinating motor output and regulating sleep and anxiety states. In humans it helps set muscle tone through inhibitory interneurons in spinal and supraspinal motor pathways. The balance between excitatory neurotransmitters such as glutamate and inhibitory GABA is fundamental to stable brain function.

Pharmacology, clinical relevance and research

Because GABAergic transmission controls excitability, it is a major therapeutic target. Drugs that enhance GABA-A receptor function — including benzodiazepines, certain hypnotics and barbiturates — produce sedative, anxiolytic and anticonvulsant effects. Ethanol and several general anesthetics also potentiate GABA‑mediated inhibition. GABA-B agonists such as baclofen are used to reduce spasticity. Conversely, inhibitors of GABA synthesis or breakdown can affect seizure thresholds and are used in epilepsy management (for example, agents that inhibit GABA transaminase increase GABA levels).

Alterations in GABA signalling are implicated in disorders including epilepsy, anxiety disorders, insomnia, some movement disorders and developmental conditions. Research continues into how GABAergic circuits develop and how modulation of specific receptor subtypes can yield more selective therapies with fewer side effects.

Notable distinctions and organisms

Although GABA is commonly called an amino acid, it differs from the protein building blocks discussed in biochemistry texts; it is not incorporated into proteins. In many mammals and vertebrates GABA is inhibitory, but in some invertebrate systems the effect can be excitatory or differ by receptor subtype — for example, certain insect receptors respond to GABA with effects tuned to their particular ionic gradients. At the cellular level GABA acts at and between neurons to modulate network activity and is a central focus of neurophysiology and clinical neuroscience.

For further basic definitions and introductions to related topics see: amino acid summaries and overview pages on neural signalling, which provide context for GABA’s role among other neurotransmitters.